09 Jan 2025

Xbrane Biopharma AB (publ) (“Xbrane” or “the company) appoints Jane Benyamin as acting Chief Financial Officer.

31 Dec 2024

XBRANE RE-SUBMITS BLA FOR RANIBIZUMAB BIOSIMILAR CANDIDATE TO FDA

18 Dec 2024

Xbrane announces outcome of exercise of warrants of series TO1

02 Dec 2024

XBRANE BIOPHARMA’S PRINCIPAL OWNER SYSTEMATIC GROUP PROVIDES A SHORT-TERM LOAN OF SEK 20 M TO THE COMPANY

26 Nov 2024

Xbrane AB (publ) today announces that the company’s CFO, Anette Lindqvist, has announced her intention to retire and will leave her position during the spring of 2025.

21 Nov 2024

XBRANE BIOPHARMA ANNOUNCES NOMINATION COMMITTEE CHANGES

19 Nov 2024

Xbrane and Intas enter into a Global Licensing agreement to jointly develop Nivolumab biosimilar referencing Opdivo®

31 Oct 2024

XBRANE BIOPHARMA PRESENTS NOMINATION COMMITTEE

24 Oct 2024

Xbrane Biopharma releases Interim Report for January-September 2024

21 Oct 2024

XBRANE PROVIDES UPDATE ON THE ONGOING OUT-LICENSING OF XDIVANE™ (NIVOLUMAB BIOSIMILAR CANDIDATE) AND XB003 (CIMZIA® BIOSIMILAR CANDIDATE) AND ITS FINANCIAL POSITION

21 Oct 2024

Invitation to presentation of Xbrane Biopharma’s interim report January – September 2024 on October 24, 2024

27 Sep 2024

Xbrane provides update from Scientific Advice with US FDA on Xdivane™ (Opdivo® biosimilar candidate)

28 Aug 2024

Xbrane Biopharma releases Interim Report for January-June 2024

23 Aug 2024

Invitation to presentation of Xbrane Biopharma’s interim report January – June 2024 on August 28, 2024

12 Aug 2024

Xbrane provides update on the ongoing out-licensing of Xdivane™ (nivolumab biosimilar candidate) and XB003 (Cimzia® biosimilar candidate) and its financial position